MA58726A1 - Forme cristalline du tétrachlorhydrate de triéthylènetétramine et utilisation pharmaceutique correspondante - Google Patents

Forme cristalline du tétrachlorhydrate de triéthylènetétramine et utilisation pharmaceutique correspondante

Info

Publication number
MA58726A1
MA58726A1 MA58726A MA58726A MA58726A1 MA 58726 A1 MA58726 A1 MA 58726A1 MA 58726 A MA58726 A MA 58726A MA 58726 A MA58726 A MA 58726A MA 58726 A1 MA58726 A1 MA 58726A1
Authority
MA
Morocco
Prior art keywords
crystalline form
triethylenetetramine tetrachloride
triethylenetetramine
tetrachloride
pharmaceutical use
Prior art date
Application number
MA58726A
Other languages
English (en)
Inventor
Timothy James Morley
Ronnie Maxwell Lawrence
Naseem Amin
Original Assignee
Orphalan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62455418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA58726(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orphalan filed Critical Orphalan
Publication of MA58726A1 publication Critical patent/MA58726A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/84—Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une nouvelle forme cristalline du tétrachlorure de triéthylènetétramine qui a une stabilité améliorée à température ambiante par rapport à des formes connues et au sel de dichlorure. La nouvelle forme cristalline est caractérisée en ce qu'elle présente des pics dans un spectre xrpd à 22,9, 25,4, 25,8, 26,6, 34,6 et 35,3 ± 0,1°2t et des décalages raman de 943, 1173, 1527 et 1612 ± 5 cm-1. La forme cristalline du tétrachlorure de triéthylènetétramine est utile dans le traitement de la maladie de wilson. L'invention concerne également un procédé de préparation d'une forme cristalline de tétrachlorure de triéthylènetétramine comprenant l'ajout d'un anti-solvant à une solution aqueuse du composé.
MA58726A 2018-05-04 2019-05-03 Forme cristalline du tétrachlorhydrate de triéthylènetétramine et utilisation pharmaceutique correspondante MA58726A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18290048 2018-05-04
PCT/EP2019/061441 WO2019211464A1 (fr) 2018-05-04 2019-05-03 Forme cristalline du tétrachlorhydrate de triéthylènetétramine et utilisation pharmaceutique correspondante

Publications (1)

Publication Number Publication Date
MA58726A1 true MA58726A1 (fr) 2023-09-27

Family

ID=62455418

Family Applications (2)

Application Number Title Priority Date Filing Date
MA51919A MA51919A1 (fr) 2018-05-04 2019-05-03 Forme cristalline du tetrachlorhydrate de triethylenetetramine et utilisation pharmaceutique correspondante
MA58726A MA58726A1 (fr) 2018-05-04 2019-05-03 Forme cristalline du tétrachlorhydrate de triéthylènetétramine et utilisation pharmaceutique correspondante

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA51919A MA51919A1 (fr) 2018-05-04 2019-05-03 Forme cristalline du tetrachlorhydrate de triethylenetetramine et utilisation pharmaceutique correspondante

Country Status (17)

Country Link
US (5) US10988436B2 (fr)
EP (1) EP3652145A1 (fr)
JP (1) JP2021531322A (fr)
KR (1) KR20210005270A (fr)
CN (3) CN119306616A (fr)
AR (1) AR115080A1 (fr)
AU (2) AU2019263969B2 (fr)
CA (1) CA3096423A1 (fr)
CO (1) CO2020013806A2 (fr)
DE (1) DE19724752T1 (fr)
EA (1) EA202092241A1 (fr)
ES (1) ES2769049T1 (fr)
MA (2) MA51919A1 (fr)
SA (1) SA520420467B1 (fr)
SG (1) SG11202010785UA (fr)
TW (1) TW202002956A (fr)
WO (1) WO2019211464A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210005270A (ko) * 2018-05-04 2021-01-13 오르파란 트리에틸렌테트라민 테트라클로라이드의 결정형 및 이의 약제학적 용도
KR102489293B1 (ko) * 2020-10-15 2023-01-17 (주) 에프엔지리서치 공업용 등급의 트리에틸렌테트라민의 고순도 정제 방법
AR125456A1 (es) 2021-04-26 2023-07-19 Orphalan S A Control de la concentración de cobre no ligado a la ceruloplasmina
TWI819502B (zh) 2022-02-23 2023-10-21 裕捷股份有限公司 一種三伸乙基四胺四氫氯化物及其製備方法與組合物
CN116675607A (zh) * 2022-02-23 2023-09-01 裕捷股份有限公司 一种三亚乙基四胺四氢氯化物及其制备方法与组合物
WO2024018394A1 (fr) * 2022-07-19 2024-01-25 Biophore India Pharmaceuticals Pvt. Ltd Procédé de préparation de la forme cristalline a du tétrachlorhydrate de n,n'-bis(2-aminoéthyl)-1,2-éthanediamine
EP4487839A1 (fr) 2023-07-03 2025-01-08 Alfred E. Tiefenbacher (GmbH & Co. KG) Forme pharmaceutique comprenant du tétrahydrochlorure de trientine et son procédé de préparation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1078731A (fr) 1976-12-16 1980-06-03 Charles E. Frosst And Co. Kit de radiographie des os, utilisant le triethylene tetramine hexa (acide methylenephosphonique)
CS197093B1 (cs) * 1978-06-16 1980-04-30 Ivo Kuhr Způsob přípravy čistého dihydrochloridu triethylentetraminu
DE19724752A1 (de) 1997-04-24 1998-11-05 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von Entzündungen und Wunden der Haut
EP1075254A2 (fr) 1998-04-03 2001-02-14 Theodore Toney Ilenchuk Utilisation de polyamines dans le traitement de symptomes dermatologiques
JP4369003B2 (ja) 2000-02-23 2009-11-18 ハリマ化成株式会社 ハンダ付け用フラックス
DK1487431T3 (da) 2002-03-08 2012-08-20 Philera New Zealand Ltd Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl
WO2003075910A1 (fr) 2002-03-08 2003-09-18 Protemix Corporation Limited Prevention et/ou traitement d'une maladie vasculaire, d'une cardiomyopathie et/ou d'une defaillance cardiaque associee
WO2004017957A1 (fr) 2002-08-20 2004-03-04 Protemix Corporation Limited Prevention et/ou traitement de maladies cardio-vasculaires et/ou insuffisance cardiaque associee
NZ545724A (en) 2003-03-18 2007-11-30 Protemix Corp Ltd Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure
PT1778618E (pt) 2004-07-19 2014-03-04 Philera New Zealand Ltd Síntese de trietilenotetraminas
CN105753719B (zh) * 2014-12-17 2019-06-21 四川科瑞德凯华制药有限公司 一种盐酸曲恩汀化合物
JP6326477B2 (ja) 2015-12-25 2018-05-16 三洋化成工業株式会社 高分子凝集剤
KR20210005270A (ko) * 2018-05-04 2021-01-13 오르파란 트리에틸렌테트라민 테트라클로라이드의 결정형 및 이의 약제학적 용도
WO2020006027A1 (fr) 2018-06-29 2020-01-02 Sharp Laboratories Of America, Inc. Conception ultra fiable de canal physique de commande de liaison montante (pucch) de nouvelle radio (nr) de 5e génération (5g)
CN109076617B (zh) 2018-07-25 2022-08-19 北京小米移动软件有限公司 Mtc系统的随机接入方法、装置及存储介质
TWI819502B (zh) 2022-02-23 2023-10-21 裕捷股份有限公司 一種三伸乙基四胺四氫氯化物及其製備方法與組合物

Also Published As

Publication number Publication date
US11117855B2 (en) 2021-09-14
CN111479798A (zh) 2020-07-31
US20200392068A1 (en) 2020-12-17
CO2020013806A2 (es) 2021-01-29
ES2769049T1 (es) 2020-06-24
US20210163398A1 (en) 2021-06-03
CN119306616A (zh) 2025-01-14
US10988436B2 (en) 2021-04-27
US20210188761A1 (en) 2021-06-24
US11072577B2 (en) 2021-07-27
EA202092241A1 (ru) 2021-04-01
BR112020018451A2 (pt) 2020-12-29
TW202002956A (zh) 2020-01-16
SA520420467B1 (ar) 2024-04-28
JP2021531322A (ja) 2021-11-18
US20240360071A1 (en) 2024-10-31
DE19724752T1 (de) 2020-07-09
SG11202010785UA (en) 2020-11-27
AR115080A1 (es) 2020-11-25
WO2019211464A1 (fr) 2019-11-07
EP3652145A1 (fr) 2020-05-20
MA51919A1 (fr) 2021-11-30
CN114394904A (zh) 2022-04-26
CA3096423A1 (fr) 2019-11-07
AU2019263969B2 (en) 2024-08-01
KR20210005270A (ko) 2021-01-13
AU2019263969A1 (en) 2020-10-22
US20220169594A1 (en) 2022-06-02
AU2024227767A1 (en) 2024-11-21
CN111479798B (zh) 2024-11-01

Similar Documents

Publication Publication Date Title
MA58726A1 (fr) Forme cristalline du tétrachlorhydrate de triéthylènetétramine et utilisation pharmaceutique correspondante
He et al. Visible-light-induced, copper-catalyzed three-component coupling of alkyl halides, olefins, and trifluoromethylthiolate to generate trifluoromethyl thioethers
ES2551898T3 (es) Derivado de benceno o tiofeno y su uso como inhibidor de la enzima VAP-1
HUP0203107A2 (hu) Új spirovegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítményekre
CA2206005C (fr) Derives d'aniline a activite inhibant la monoxyde d'azote synthase
CA2489209A1 (fr) Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
MA48798B1 (fr) Procédé de production d'ozanimod
JP2016513663A5 (fr)
Mixdorf et al. Asymmetric synthesis of allylic fluorides via fluorination of racemic allylic trichloroacetimidates catalyzed by a chiral diene-iridium complex
CA2206794A1 (fr) Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
MA39688B1 (fr) Composés hétéroaryle pour le traitement de maladies ophtalmiques
TN2009000018A1 (fr) Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
CA3037554A1 (fr) Procede de preparation d'acides (1r,3r)- et (1s,3s)-2,2-dihalo-3-(phenyle substitue) cyclopropanecarboxylique
CA2519110A1 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation dans le traitement de la douleur
FR3037953B1 (fr) Procede de synthese de molecules portant une fonction oxyde de nitrile
Khoobi et al. Highly cis‐Diastereoselective Synthesis of Coumarin‐Based 2, 3‐Disubstituted Dihydrobenzothiazines by Organocatalysis
MA41186B1 (fr) Nouvelles formes de cristal du sel monosodique de foramsulfuron
RU2663899C1 (ru) Способ получения 1-карбамоилметил-4-фенил-2-пирролидона
FI68808C (fi) Foerfarande foer framstaellning av bromhexin och en ny dibromfoerening foer anvaendning som mellanprodukt vid foerfarandet
HUP0400869A2 (hu) Fenileténszulfonamid-pirimidin-származék új kristályalakjai, valamint eljárás ezek előállítására
JP5656474B2 (ja) 脂肪族光学活性フルオロアルコールの製造方法
KR100468066B1 (ko) （３ａＳ）-５,５-디옥소-２,3,３ａ,４-테트라히드로-１Ｈ-피롤로〔２,１-ｃ〕〔１,２,４〕벤조티아디아진의 합성 방법
Dai et al. Synthesis of Aromatic Sphingosine Analogues by Diastereoselective Amination of Enantioenriched trans-γ, δ-Unsaturated β-Hydroxyesters
US2805234A (en) Process for production of tetra-alkyl tin compound having at least 10 carbon atoms per alkyl radical
JPH07196589A (ja) ホモキラルアミノアルコールの製法